TITLE

Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate

AUTHOR(S)

Vasisht, Niraj; Gever, Larry N.; Tagarro, Ignacio; Finn, Andrew L.

PUB. DATE

October 2009

SOURCE

Clinical Drug Investigation;2009, Vol. 29 Issue 10, p647

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background and Objectives: BioErodible MucoAdhesive (BEMA®) is a new transmucosal drug delivery system designed to improve and ease the administration of drugs by this route. The first product that uses this novel delivery system contains fentanyl and is intended for the treatment of breakthrough pain in opioid-tolerant patients with cancer. The generic name is fentanyl buccal soluble film (FBSF). The objectives of this study were to compare the pharmacokinetic profile of FBSF formulations at three different pHs (pH 6, pH 7.25 and pH 8.5) and to understand the differences in the pharmacokinetics of fentanyl from FBSF compared with that of oral transmucosal fentanyl citrate (OTFC). Methods: This was a randomized, open-label, single-dose, four-period, Latinsquare crossover study consisting of a 9-day inpatient treatment period. The study was conducted at a phase 1 clinical research unit in Austin, TX, USA. Twelve healthy subjects were enrolled, nine males and three females, between the ages of 21 and 44 years. Each subject received four 800 mg doses of fentanyl: single doses of the three FBSF formulations (pH 6, pH 7.25 and pH 8.5) and OTFC, with concurrent naltrexone. Plasma fentanyl concentrations were measured over a 48-hour period after each study dose. Pharmacokinetic parameters were calculated and compared. Results: Peak plasma fentanyl concentrations (Cmax) and overall fentanyl systemic exposure (area under the plasma concentration-time curve from time zero extrapolated to infinity [AUC∞]) for each of the three FBSF formulations were greater than for OTFC. The pH 7.25 FBSF formulation provided the earliest time to reach Cmax (tmax), the highest Cmax value and the greatest AUC∞ value. Compared with OTFC, peak plasma fentanyl concentrations with pH 7.25 FBSF were significantly higher (mean Cmax 1.67 vs 1.03 ng/mL; p < 0.05). Overall exposure was also greater with pH 7.25 FBSF than with OTFC (mean AUC∞ 14.5 vs 10.3 ng•h/mL). Conclusions: All three FBSF formulations produced greater peak plasma concentrations and overall exposure to fentanyl than OTFC. In particular, the pH 7.25 FBSF formulation showed the most favourable pharmacokinetic profile of the three FBSF formulations. In comparison with OTFC, the pH 7.25 FBSF formulation produced the fastest and most efficient fentanyl delivery and was selected for further clinical development.

ACCESSION #

44256030

 

Related Articles

• Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial. Shimoyama, Naohito; Gomyo, Ikuo; Katakami, Nobuyuki; Okada, Masakuni; Yukitoshi, Nobuyuki; Ohta, Eri; Shimoyama, Megumi // International Journal of Clinical Oncology;Feb2015, Vol. 20 Issue 1, p198 

  Background: Breakthrough cancer pain typically has a rapid onset and relatively short duration. Due to this temporal profile, it may not be adequately relieved by oral opioid analgesics. The sublingual fentanyl orally disintegrating tablet is a formulation by which fentanyl can be rapidly...

• Fentanyl Pectin Nasal Spray: In Breakthrough Pain in Opioid-Tolerant Adults with Cancer. Lyseng-Williamson, Katherine A. // CNS Drugs;2011, Vol. 25 Issue 6, p511 

  Fentanyl pectin nasal spray (PecFent®) uses a novel pectin-based delivery system that turns from an aqueous solution into a gel when applied to mucosal surfaces. Fentanyl is absorbed in a controlled manner from the pectin gel formed in the nasal cavity, and has a rapid onset of pain relief...

• Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Mercadante, Sebastiano; Vellucci, Renato; Cuomo, Arturo; Adile, Claudio; Cortegiani, Andrea; Valle, Alessandro; Villari, Patrizia; Casuccio, Alessandra // Supportive Care in Cancer;May2015, Vol. 23 Issue 5, p1349 

  Purpose: The aim of the present study was to assess the long-term tolerability and efficacy of intranasal fentanyl (INFS) in opioid-tolerant patients with breakthrough cancer pain (BTP). Patients and methods: A 6 months, observational, prospective, cohort study design was employed to follow...

• Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Davies, Andrew; Kleeberg, Ulrich; Jarosz, Jerzy; Mercadante, Sebastiano; Poulain, Philippe; O'Brien, Tony; Schneid, Hélène; Kress, Hans // Supportive Care in Cancer;Jul2015, Vol. 23 Issue 7, p2135 

  Purpose: This open-label study evaluated the effects of fentanyl buccal tablet (FBT) on functioning and mood in cancer patients with breakthrough cancer pain (BTcP). Methods: Opioid-tolerant patients in seven European countries with up to four BTcP episodes/day received FBT doses (100-800 μg)...

• Indicators of Drug-Seeking Aberrant Behaviours: The Feasibility of Use in Observational Post-Marketing Cohort Studies for Risk Management. Layton, Deborah; Osborne, Vicki; Al-Shukri, Mohammad; Shakir, Saad // Drug Safety;Aug2014, Vol. 37 Issue 8, p639 

  Background: Problematic prescription drug use is reflected by or associated with drug-seeking aberrant behaviours. Research gaps include lack of post-marketing evidence and instruments. As part of the pharmacovigilance requirements, a risk management plan was developed for fentanyl buccal...

• Management of Pain in Patients with Cancer. Miller, Karl E. // American Family Physician;2/1/2000, Vol. 61 Issue 3, p835 

  Discusses research on management of pain in cancer patients. Reference to a study by J. L. Abrahm, from the July 6, 1999 issue of the `Annals of Internal Medicine'; Problems of pain and spinal cord compression experienced by cancer patients; Assessment of pain intensity; Prescription of opioids...

• Treating neuropathic pain in cancer. Harman, Stephanie // Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p34 

  The article presents information on the treatment of neuropathic pain in patients diagnosed with cancer.

• The Role of Fentanyl in Cancer-Related Pain. Prommer, Eric // Journal of Palliative Medicine;Oct2009, Vol. 12 Issue 10, p947 

  Fentanyl is a lipophilic, short-acting, synthetic opioid with a piperidine chemical structure. Fentanyl is an effective analgesic for cancer pain, and newer formulations such as the transmucosal and buccal forms have shown efficacy for the management of cancer-related breakthrough pain. This...

• Is there enough evidence to advocate opioid combinations? Does one and one make two or more? Zylicz, Zbigniew; Mercadante, Sebastiano // Advances in Palliative Medicine;2010, Vol. 9 Issue 2, p31 

  Despite a more than tenfold increase in opioid consumption in the past decades, many cancer patients still suffer pain. The current understanding of this situation is poorly understood. It is still possible that in some countries pain is still undertreated, but it is also possible that we do not...

Read the Article